Vaxcyte

PCVXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.843 B

$62.18 -5.33%

Close of 6 Nov 2026

As of 6 Nov 2026, Vaxcyte (PCVX) has a market capitalization of $9.84B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$766.6K

Loss-making

Shares outstanding

158,299,981

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#13RepligenRGEN$10.8B
#14QiagenQGEN$10.5B
#15VaxcytePCVX$9.84B
#16Krystal BiotechKRYS$8.92B
#17ImmunityBioIBRX$8.48B

What if Vaxcyte were worth as much as…

Open the what-if tool →

Gold $28.2T

$178,375.72

Per share 2,869× higher

Bitcoin $1.53T

$9,651.60

Per share 155× higher

Apple $5.02T

$31,685.30

Per share 510× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Vaxcyte are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.